Doximity checks point to better-than-expected growth in Q3, says Morgan Stanley

Morgan Stanley analyst Craig Hettenbach says the firm’s latest checks point to better-than-expected growth in calendar Q3 and positive sentiment toward a calendar Q4 budget flush, with Doximity’s (DOCS) video modules the driving force behind a reacceleration in its growth, consistent with prior checks. The firm, which adds that it finds “no impact” and no overlap with OpenEvidence to date, has an Equal-weight rating and $62 price target on Doximity shares.